参考文献
(在框内滑动手指即可浏览)
[1] Bray F,Ferlay J,Soerjomataram I,et a1.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68 (8):394-424.
[2] Zahedi A, Bondaz L, Rajaraman M,et al. Risk for thyroid cancer recurrence is higher in men than in women independent of disease stage at presentation[J]. Thyroid,2020,30(6):871-877.
[3] 中华人民共和国国家卫生健康委员会.甲状腺癌诊疗规范(2018 年版) [J].中华普通外科学文献(电子版) ,2019,13(1) : 1-15.
[4] Bates MF, Lamas MR, Randle RW, et al. Back so soon? Is early recurrence of papillary thyroid cancer really just persistent disease? [J]. Surgery, 2018, 163( 1) : 118.
[5] Bates MF,Lamas MR, Randle RW, et al.Back so soon`? Is early rec- urrence of papillary thyroid cancer really just persistent diseas? [J].Surgery,2018,163(1):118.
[6] Reese J,Chebolu A,Shen YJ,et al. Case report: diffuse metastatic infiltration of the thyroid by esophageal adenocarcinoma mimicking non -neoplastic thyroid disease[J].Radiol Case Rep,2017,13(1):108-111.
[7] Seo JW,Han K,Lee J,et al. Application of metabolomics in prediction of lymph node metastasis in papillary thyroid carcinoma[J]. PLoS One,2018,13(3):e0193883.
[8] Haugen BR, Alexander EK. Bible KC,et a1.2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer:the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer[J].Thyroid,2016,26(1):1-133.
[9] 伍波,樊友本.我国甲状腺癌治疗现状:不足、不规范和过度并存[J].浙江医学,2017,39(11):857-859,870.
[10] 田文,姚京.甲状腺全切除术在甲状腺癌外科治疗中的价值及合理选择[J].中国实用外科杂志,2014,34(1):52-54,58.
[11] 吴俊峰.甲状腺大部切除术治疗甲状腺癌对复发率及喉返神经损伤情况观察[J].智慧健康,2020,6(36):78-79.
[12] Patel KN,Yip L,Lubitz CC,et a1.The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Thyroid Disease in Adults[J].Ann Surg,2020,271 (3):e21-e93.
[13] 陈端浩,滕辉.分化型甲状腺癌不同手术方式对术后并发症和预后的影响[J].深圳中西医结合杂志,2020,30(21):115-117.
[14] 田文,郗洪庆.分化型甲状腺癌外科诊疗进展及展望[J].中国实用外科杂志,2020,40(1):78-82.
[15] 中国医师协会外科医师分会甲状腺外科医师委员会,中国研究型医院学会甲状腺疾病专业委员会. 分化型甲状腺癌术后管理中国专家共识(2020 版)[J]. 中国实用外科杂志,2020,40(9):1021-1028.
[16] Ryu YJ,Kang SJ,Cho JS,et al. Identifying risk factors of lateral lymph node recurrence in clinically node-negative papillary thyroid cancer[J].Medicine,2018,97(51) : e13435
[17] 徐志勇,马晓良.甲状腺癌患者术后复发风险预测的列线图模型建立[J].实用肿瘤学杂志,2021,35(1):35-40.
[18] Vaisman F,Shaha A,Fish S,et al. Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer[J].Clin Endocrinol(Oxf),2011,75(1): 112-119.
[19] Netzel BC,Grebe SK,Carranza Leon BG,et al. Thyroglobulin (Tg)testing revisited: Tg assays,TgAb assays,and correlation of results with clinical outcomes[J].J Clin Endocrinol Metab,2015,100(8):1074-1083.
[20] Durante C,Tognini S,Montesano T,et al. Thyroglobulin (Tg)testing revisited: Tg assays,TgAb assays,and correlation of results with clinical outcomes[J]. Thyroid,2014,24(7):1139-1145.
[21] Rosignolo F,Sponziello M,Giacomelli L,et al. Identification of Thyroid- Associated Serum microRNA Profiles and Their Potential Use in Thyroid Cancer Follow- Up[J]. J Endocr Soc,2017,1(1):3-13.
[22] Lee JC,Zhao JT,Clifton- Bligh RJ,et al. MicroRNA- 222 and microRNA- 146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer[J]. Cancer,2013,119(24):4358-4365.
[23] Nixon AM,Provatopoulou X,Kalogera E,et al. Circulating thyroid cancer biomarkers: Current limitations and future prospects[J]. Clin Endocrinol (Oxf), 2017, 87(2):117-126.
[24] Zeng H,Chen W,Zheng R,et al.Changing cancer survival in China during 2003- 15: a pooled analysis of 17 populationbased cancer registries[J].Lancet Glob Health,2018,6(5):e555-e567.
[25] Miller KD,Nogueira L,Mariotto AB,et al.Cancer treatment and survivorship statistics,2019[J].CA Cancer J Clin,2019,69(5): 363-385.
[26] 田文,郗洪庆,王冰.重视甲状腺癌术后规范化长期随访[J].中国实用外科杂志,2017,37(9):937-940.
[27] 糜泽花,钱爱兵.智慧医疗发展现状及趋势研究文献综述[J].中国全科医学,2019,22(3):366-370.
[28] 朱国华,邹贤,王国瑞,等.持续/复发分化型甲状腺癌二次手术生存的影响因素[J].中国肿瘤外科杂志,2020,12(6):571-575.
[29] 张立阳,刘春浩,曹越,等.125例复发/持续性分化型甲状腺癌再次手术及其预后影响因素分析[J].中国癌症杂志,2019,29(6):412-417.
[30] 毛雨,任浩宇,胡代星,等.222例分化型甲状腺癌再手术的临床分析[J].中国肿瘤外科杂志,2019,11(2):121-124.
[31] Ferrari SM,Elia G,Ragusa F,et al.Novel treatments for anaplastic thyroid carcinoma[J].Gland Surg,2020,9(suppl1):S28-S42.
[32] Tahara M, Kiyota N, Yamazaki T, et al.Lenvatinib for anaplastic thyroid cancer[J].Front Oncol,2017,7:25.
[33] Nahum GE, Morkos M, Kim B, et al. Novel targeted therapies and immunotherapy for advanced thyroid cancers[J].Mol Cancer,2018,17(1): 51.
[34] Antonelli A, Ferrari SM, Fallahi P. Current and future immunotherapies for thyroid cancer[J].Expert Rev Anticancer Ther,2018, 18(2): 149-159.
[35] 田文,郗洪庆,万政.甲状腺癌多学科综合诊疗的现状与展望[J].中华内分泌外科杂志,2021,15(1):1-4.
[36] 杨亚,梁晨,陈桢,等.国内外多学科诊疗模式研究进展分析[J].中国卫生质量管理,2021,28(2):16-19.